News


All series


All News

A new retrospective analysis of 640 newly diagnosed patients with follicular lymphoma found that patients who had achieved partial remission after 4 or more cycles of bendamustine plus rituximab experienced improved duration of response on maintenance rituximab compared with patients who received no maintenance treatment or who were in complete remission following induction with bendamustine plus rituximab.

Bristol-Myers Squibb has announced its decision to withdraw a supplemental biologics license application currently with the FDA seeking frontline approval for the combination of nivolumab and ipilimumab for patients with advanced non–small cell lung cancer with tumor mutational burden ≥10 mutations per megabase.

Both overall survival and progression-free survival were improved in patients with <em>EGFR</em>-mutant nonsquamous cell lung cancer who were treated with the combination of atezolizumab, bevacizumab, and chemotherapy compared with bevacizumab plus chemotherapy, according to an exploratory analysis of the IMpower150 study.

A partial clinical hold has been placed on the&nbsp;phase III AIM2CERV trial by the FDA, Advaxis, Inc. has announced.<sup>1</sup> The trial is evaluating the use of the investigational immunotherapy agent axalimogene filolisbac in high-risk locally advanced cervical cancer.

Despite all the positive data associated with PARP inhibitors for the treatment of patients with&nbsp;epithelial ovarian cancer who have known <em>BRCA</em> mutations, these agents are not curing patients, said Leslie M. Randall, MD, MAS, at the 2019 SGO Annual Winter Meeting.

Updated data from the JULIET trial,&nbsp;which were presented at the 2018 ASH Annual Meeting, underscore the impact of&nbsp;tisagenlecleucel for patients with diffuse large B-cell lymphoma, said&nbsp;Richard T. Maziarz, MD, the trial&#39;s lead investigator.

A prospective, observational study recently published in the&nbsp;<em>European Journal of Cancer&nbsp;</em>helped to clarify the prognostic role of&nbsp;<em>TERT&nbsp;</em>promoter mutations among patients with localized thyroid cancer, revealing that&nbsp;<em>TERT&nbsp;</em>mutations were associated with poor outcomes among patients with nonmetastatic disease that do not have an aggressive histology.

FDA approval is being sought for the combination of&nbsp;daratumumab with&nbsp;lenalidomide and dexamethasone for the treatment of newly diagnosed patients with multiple myeloma who are not candidates for high-dose chemotherapy and autologous stem-cell transplant. Genmab,&nbsp;which co-develops daratumumab with Janssen Biotech, announced that a&nbsp;supplemental Biologics License Application has been initiated with the FDA.